

Summary Public Assessment Report

Axhidrox (glycopyrronium bromide)

SE/H/2141/01/DC

Summary Public Assessment Report

Axhidrox
glycopyrronium bromide

Cream, 2.2 mg/ pump actuation

This is a summary of the public assessment report (PAR) for Axhidrox. It explains how Axhidrox was assessed and its authorisation recommended as well as its conditions of use. It is not intended to provide practical advice on how to use Axhidrox.

For practical information about using Axhidrox, patients should read the package leaflet or contact their doctor or pharmacist.

What is Axhidrox and what is it used for?

Axhidrox contains the active substance glycopyrronium as glycopyrronium bromide and belongs to a group of sweat reducing medicines called antihidrotics.

Axhidrox is used for topical treatment of severe primary axillary hyperhidrosis in adults and adolescents 12 years of age and older.

How does Axhidrox work?

Primary axillary hyperhidrosis causes excessive sweating in both armpits without any apparent reason like sports, hard physical work, hot weather, certain diseases or medicines. A feature of primary axillary hyperhidrosis is that it occurs usually during the day but not during sleep. External use of Axhidrox in the armpits leads to reduced sweat production in the sweat glands.

How is Axhidrox used?

The pharmaceutical form of Axhidrox is a cream for use only on the skin in your armpits.

Please read section 3 of the package leaflet for detailed information on dosing recommendations, the route of administration, and the duration of treatment.

The medicine can only be obtained with a prescription in Sweden.

What benefits of Axhidrox have been shown in studies?

The company provided its own data on efficacy and safety studies. These studies have shown that Axhidrox is effective in treating severe primary axillary hyperhidrosis.

What are the possible side effects from Axhidrox?

For the full list of side effects, see section 4 of the package leaflet.

For the full list of restrictions, see the package leaflet.

Why is Axhidrox approved?

The Swedish Medical Products Agency decided that Axhidrox's benefits are greater than its risks and recommended that it can be approved for use.

What measures are being taken to ensure the safe and effective use of Axhidrox?

A risk management plan has been developed to ensure that Axhidrox is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Axhidrox, including the appropriate precautions to be followed by healthcare professionals and patients.

Known side effects are continuously monitored. Furthermore, new safety signals reported by patients/healthcare professionals will be monitored/reviewed continuously as well.

Other information about Axhidrox

The full PAR for Axhidrox can be found on the following website:

<http://mri.medagencies.org/Human/>. For more information about treatment with Axhidrox, please read the package leaflet or contact your doctor or pharmacist.

This summary was last updated in 2026-02.